Work

A randomised phase II study of azacitidine ( AZA ) alone or with Lenalidomide ( LEN ), Valproic acid ( VPA ) or Idarubicin ( IDA ) in higher‐Risk MDS or low blast AML : GFM 's “pick a winner” trial, with the impact of somatic mutations

Year: 2022
Type: article
Study design: Clinical Trial
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: closed
OpenAlex ID: W4224234210
FWCI: 3.078
Cites: 28
Cited by: 21
Related to: 10